• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Anesthesiology >Dexmedetomidine and sufentanil combination versus sufentanil alone for postoperative intravenous patient-controlled analgesia: a systematic review and meta-analysis of randomized controlled trials
【24h】

Dexmedetomidine and sufentanil combination versus sufentanil alone for postoperative intravenous patient-controlled analgesia: a systematic review and meta-analysis of randomized controlled trials

机译：右美托咪定联合舒芬太尼与单独舒芬太尼联合用于术后静脉自控镇痛：随机对照试验的系统评价和荟萃分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Previous studies have demonstrated that dexmedetomidine improves the quality of postoperative analgesia. In the present study, we performed a meta-analysis of randomized controlled trials to quantify the effect of dexmedetomidine as an adjuvant to sufentanil for postoperative patient-controlled analgesia (PCA). PubMed, Embase, the Cochrane Library, and Web of Science were systematically searched for randomized controlled trials in which dexmedetomidine was used as an adjuvant for PCA with sufentanil. In the retrieved studies, we quantitatively analyzed pain intensity, sufentanil consumption, and drug-related side effects. Nine studies with 907 patients were included in this meta-analysis. Compared with sufentanil alone, dexmedetomidine-sufentanil for postoperative intravenous PCA reduced pain intensity at 24?h (mean difference (MD)?=???0.70points; 95% confidence interval (CI): ??1.01, ??0.39; P??0.00001) and 48?h postoperatively (MD?=?-0.61points; 95% CI: ??1.00, ??0.22; P?=?0.002). Moreover, dexmedetomidine-sufentanil reduced sufentanil consumption during the first 24?h (MD?=?-13.77?μg; 95% CI: ??18.56, ??8.97; P??0.00001) and 48?h postoperatively (MD?=?-20.81?μg; 95% CI: ??28.20, ??13.42; P??0.00001). Finally, dexmedetomidine-sufentanil improved patient satisfaction without increasing the incidence of side effects. Dexmedetomidine as an adjuvant to sufentanil for postoperative PCA can reduce postoperative pain score and sufentanil consumption.
机译：先前的研究表明右美托咪定可改善术后镇痛的质量。在本研究中，我们进行了一项随机对照试验的荟萃分析，以量化右美托咪定作为舒芬太尼的佐剂对术后患者自控镇痛（PCA）的作用。系统地搜索PubMed，Embase，Cochrane图书馆和Web of Science的随机对照试验，其中将右美托咪定用作舒芬太尼PCA的佐剂。在检索的研究中，我们定量分析了疼痛强度，舒芬太尼的消耗量以及与药物相关的副作用。这项荟萃分析包括9项针对907例患者的研究。与单独使用舒芬太尼相比，右美托咪定-舒芬太尼用于术后静脉内PCA在24？h时可减轻疼痛强度（平均差（MD）== 0.70分; 95％置信区间（CI）：≥1.01，≤0.39; P ＜＜ 0.00001）和术后48小时（MD ＜＝β-0.61点; 95％CI：≤1.00，≤0.22;P≤0.002）。此外，右美托咪定舒芬太尼在术后24小时（MD ==-13.77µg; 95％CI：≥18.56，≥8.97; P 0.00001）和术后48小时（MD≥18）减少了舒芬太尼的消耗。 ＝Δ-20.81μg; 95％CI：Δ28.20，Δ13.42;P≤＜0.00001）。最后，右美托咪定-舒芬太尼在不增加副作用发生率的情况下提高了患者满意度。右美托咪定作为舒芬太尼用于术后PCA的佐剂可以减少术后疼痛评分和舒芬太尼的消耗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号